Development of technology for regulation and quality control of immune cells in cancer therapy

The new technology using glycomics proved to be useful for T cell immunity against tumor cells. Using quality-controlled T cell by this technology should be advantageous for future immune therapy against cancer. Chemokines and neural guidance factors involved in the regulation of T cell infiltration will be also planned to modulate as additional potential targets. Chimera antigen receptor (CAR) therapy, in which T cells are engineered to express CAR specific for certain cancer and transferred back to their own cancer host, is next promising immune therapy against cancer. We will focus on establishment of novel CAR therapy. CAR highly specific for cancer cells as well as quality of T cells are critical for CAR therapy. We developed new biological assay to screen CAR, which overcome the ordinal time-consuming screening steps. Combined with two technologies, we will establish new technology for cancer therapy.